<DOC>
	<DOCNO>NCT02689843</DOCNO>
	<brief_summary>The aim study evaluate effect three-month course treatment modality ( Cyproterone compound-Spironolactone , Metformin Pioglitazone ) patient polycystic ovary syndrome ( PCOS ) marker inflammation [ serum complement , homocysteine high sensitive C-reactive protein ( hs-CRP ) ] level .</brief_summary>
	<brief_title>Effects Cyproterone Compound-spironolactone , Metformin Pioglitazone Inflammatory Markers PCOS</brief_title>
	<detailed_description>Polycystic ovary syndrome ( PCOS ) estimate affect to10 % woman reproductive age , make one common endocrine disorder population . PCOS associate broad range adverse sequel , include hypertension , dyslipidemia , insulin resistance , hyperandrogenaemia , gestational type 2 diabetes , ultimately increase cardiovascular morbidity patient . Also PCOS increasingly recognize component metabolic syndrome . Management depend symptom source androgen excess . Several treatment option available , allow individualized approach . Spironolactone safe potent available antiandrogen . It effective lower hirsutism score approximately one third , although considerable individual variation exist . Other antiandrogens use treat hirsutism hirsutism equivalent include cyproterone acetate weak antiglucocorticoid effect . Metformin thiazolidinediones , promise adjunct treat PCOS . Although increase insulin sensitivity , mechanism action differ . Serum complement , homocysteine C-reactive protein ( CRP ) level report link insulin resistance . The investigator want measure serum complement , homocysteine hs-CRP level patient PCOS three-month course treatment Cyproterone compound-Spironolactone ( CC-S ) , metformin ( M ) pioglitazone ( P ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Age 1835 year Diagnosis Polycystic Ovary Syndrome ( PCOS ) accord Rotterdam criterion 2003 ( two three require ) : 1 . Oligomenorrhea anovulation 2 . Clinical and/or biochemical sign hyperandrogenism 3 . Polycystic ovary ( ultrasound ) Smoking Pregnancy Diabetes mellitus Renal failure ( serum creatinine &gt; 1.5 ) Congenital adrenal hyperplasia Hyper hypothyroidism Sex hormone therapy antiandrogen therapy last three month Unexplained serum alanin aminotransferase ( ALT ) elevation 2.5 time normal range Any systemic febrile illness Use glucocorticoid antiinflammatory drug last three month Androgen secrete tumor Malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Complement system protein</keyword>
	<keyword>Homocysteine</keyword>
	<keyword>C-Reactive Protein</keyword>
	<keyword>Cyproterone</keyword>
	<keyword>Ethinyl Estradiol</keyword>
	<keyword>Androgen Antagonists</keyword>
	<keyword>Metformin</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>